Hemoglobin Concentration in Patients With an Acute Respiratory Distress Syndrome

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03871166

Enrollment

1044

Registered

2019-03-12

Start date

2018-08-01

Completion date

2020-11-24

Last updated

2021-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ARDS, Human

Brief summary

Retrospective analysis of hemoglobin concentrations and red cell transfusion thresholds in patients with an Acute Respiratory Distress Syndrome (ARDS) admitted to an ARDS-center of a German university hospital.

Detailed description

Transfusion of packed red blood cells is a common procedure in critically ill patients. In recent years it has been shown that for many patient populations a restrictive transfusion strategy is not inferior compared to a liberal transfusion strategy with regard to overall outcome. So far it is unclear whether patients with an ARDS should receive blood transfusions according to a restrictive or liberal transfusion strategy. Besides pulmonary gar exchange and cardiac output, the hemoglobin concentration is an important determinant for oxygen delivery. The aim of this retrospective observational study is to analyze if low levels of hemoglobin/a restrictive transfusion strategy and are associated with a different mortality compared to higher levels of hemoglobin/a liberal transfusion strategy in patients with an ARDS.

Interventions

OTHERBlood transfusion

Observational post-ad-hoc design to compare patients admitted with an ARDS and separated into different groups according to their mean hemoglobin concentration during their stay on the intensive care unit. Approximately 1000 adult patients admitted from 2007 to 2018 to the Charite ARDS center will be enrolled in the study. They are followed up until their discharge from the ICU. \[Time Frame: 01/2007 - 12/2018\]

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* All adult patients with ARDS * Admission to the Charité ARDS center

Exclusion criteria

* All patients \<18 years at the time of admission * All patients with ARDS not admitted to the Charité ARDS center

Design outcomes

Primary

Measure	Time frame	Description
Mortality	01/2007 - 12/2018	Mortality of patients with ARDS at 28 days according to transfusion threshold

Secondary

Measure	Time frame	Description
Failure-free days composites	01/2007 - 12/2018	Failure-free days composites according to transfusion threshold

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026